Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus

NCT01525238 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01525238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01525238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2012
Completion date
September 1, 2014
Enrollment
53 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus